Liver cancer is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer related deaths worldwide. Clonal evolution of a tumor ecosystem depends not only on somatic mutations driving uncontrolled growth, but also on a full array of selection pressures that are principally immune and treatment mediated. Here I integrate data from RNA-seq, targeted DNA sequencing, and SNP array technologies across multiple regions of liver cancer specimens to map spatio-temporal interactions between cancer and immune cells. I interrogate how these interactions reflect intra-tumor heterogeneity (ITH) by correlating regional neo-epitope and viral antigen burden with the magnitude and clonality of the regional adaptive immune response. Regional expression of passenger mutations dominantly recruits adaptive responses as opposed to hepatitis B virus and cancer-testis antigens. I detect lymphocyte clonal expansions in distant regions of the same tumor nodule. Leveraging the TCGA liver cancer dataset, I show that an ITH-based gene signature improves single-biopsy patient survival predictions. An expression survey of 38,553 single cells across 7 regions of 2 patients further reveals significant and highly regionally dependent heterogeneity of transcription factor activity in liver cancer cells. Overall, these data quantify the scale of transcriptomic ITH and how the different components of the liver cancer ecosystem interact during cancer evolution.
While cancer-testis antigens (CTAs) appear lowly immunogenic in liver cancer, there were patients who showed an extreme overexpression of these genes with regional variation. Specifically, approximately one third of patients from a cohort of 228 HCC samples appear to be high expressers of the CTA MAGEA3/6. MAGEA3/6 was determined to be a key causal driver of a major regulatory sub-network inferred from TCGA LIHC-HCC data. Further, MAGEA3/6 expression is also correlated with worse overall survival, poor differentiation tumor status and several gene signatures of poor prognosis. Experimentally, in a MYC; TP53 mouse model of liver cancer, the additional over-expression of MAGEA3/6 led to a significantly shorter overall survival. These data suggest an active role in liver cancer progression for MAGEA3/6.
Some files may require a special program or browser plug-in. More Information
|Commitee:||O'Connell, Matthew, Pfleger, Cathie, Lujambio, Amaia, Friedman, Scott|
|School:||Icahn School of Medicine at Mount Sinai|
|School Location:||United States -- New York|
|Source:||DAI-B 81/2(E), Dissertation Abstracts International|
|Subjects:||Oncology, Molecular biology, Immunology|
|Keywords:||Hepatocellular carcinoma, Immunogenomics, Liver cancer, Tumor heterogeneity|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be